


Journal Pre-proof

[[Translated article]]Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyrál®) still be part of the Baseline Series?

C.P. Hernández Fernández L. Borrego A.M. Giménez Arnau T. Sanz Sánchez J.M. Carrascosa Carrillo V. Zaragoza Ninet E. Serra Baldrich F.J. Miquel Miquel J.F. Silvestre Salvador S. Córdoba Guijarro A. Sánchez Gilo P. Mercader García F. Navarro Triviño F. Tous Romero M. Rodríguez Serna G. Melé Ninot I. Ruiz González E. Gómez de la Fuente M.A. Pastor Nieto P. Sánchez-Pedreño Guillén J. Sánchez Pérez J.J. Pereyra Rodríguez M.E. Gatica Ortega R. González Pérez I. García Doval M.A. Gallego Descalzo



PII: S0001-7310(25)00663-5

DOI: <https://doi.org/doi:10.1016/j.ad.2025.10.016>

Reference: AD 4483

To appear in: *Actas dermosifiliograficas*

Received Date: 9 May 2024

Accepted Date: 6 October 2024

Please cite this article as: Hernández Fernández CP, Borrego L, Giménez Arnau AM, Sanz Sánchez T, Carrascosa Carrillo JM, Zaragoza Ninet V, Serra Baldrich E, Miquel Miquel FJ, Silvestre Salvador JF, Córdoba Guijarro S, Sánchez Gilo A, Mercader García P, Navarro Triviño F, Tous Romero F, Rodríguez Serna M, Melé Ninot G, Ruiz González I, Gómez de la Fuente E, Pastor Nieto MA, Sánchez-Pedreño Guillén P, Sánchez Pérez J, Pereyra Rodríguez JJ, Gatica Ortega ME, González Pérez R, García Doval I, Gallego Descalzo MA, [[Translated article]]Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyrál®) still be part of the Baseline Series?, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2025.10.016>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 AEDV. Published by Elsevier España, S.L.U.

Refers to AD_4276

Original

¿Debe continuar el hidroxiiisohexil 3-ciclohexeno carboxaldehído (Lyrál®) en las baterías estándar de las pruebas epicutáneas?

[[Translated article]]Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyrál®) still be part of the Baseline Series?

C. P. Hernández Fernández^a, L. Borrego^b, A. M. Giménez Arnau^c, T. Sanz Sánchez^d, J. M. Carrascosa Carrillo^e, V. Zaragoza Ninet^f, E. Serra Baldrich^g, F. J. Miquel Miquel^h, J. F. Silvestre Salvadorⁱ, S. Córdoba Guijarro^j, A. Sánchez Gilo^k, P. Mercader García^l, F. Navarro Triviño^m, F. Tous Romeroⁿ, M. Rodríguez Serna^o, G. Melé Ninot^p, I. Ruiz González^q, E. Gómez de la Fuente^r, M. A. Pastor Nieto^s, P. Sánchez-Pedreño Guillén^t, J. Sánchez Pérez^u, J. J. Pereyra Rodríguez^v, M. E. Gatica Ortega^w, R. González Pérez^x, I. García Doval^y, M. A. Gallego Descalzo^y

^aServicio de Dermatología. Hospital Universitario de Gran Canaria Doctor Negrín. Universidad de Las Palmas de Gran Canaria. Las Palmas de Gran Canaria. España.

^bServicio de Dermatología. Hospital Universitario Insular de Gran Canaria. Universidad de Las Palmas de Gran Canaria. Las Palmas de Gran Canaria. España.

^cServicio de Dermatología. Hospital del Mar Research Institute. Barcelona. España.

^dServicio de Dermatología. Hospital Universitario Infanta Sofía. Madrid. España.

^eServicio de Dermatología. Hospital Universitari Germans Trias i Pujol. Barcelona. España.

^fServicio de Dermatología. Hospital General Universitario de Valencia. Valencia. España.

^gServicio de Dermatología. Hospital de la Santa Creu i Sant Pau. Barcelona. España.

^hServicio de Dermatología. Hospital Universitario Arnau de Vilanova. Valencia. España.

ⁱServicio de Dermatología. Hospital General Universitario Doctor Balmis. ISABIAL. Alicante. España.

^jServicio de Dermatología. Hospital Universitario de Fuenlabrada. Madrid. España.

^kServicio de Dermatología. Hospital Universitario Rey Juan Carlos. Madrid. España.

^lServicio de Dermatología. Hospital General Universitario Morales Meseguer. Murcia. España.

^mServicio de Dermatología. Hospital Universitario San Cecilio. Granada. España.

ⁿServicio de Dermatología. Hospital Universitario 12 de Octubre. Madrid. España.

^oServicio de Dermatología. Hospital Universitario La Fe. Valencia. España.

^pServicio de Dermatología. Hospital Universitari Sagrat Cor, Grupo Quirónsalud. Barcelona. España.

^qServicio de Dermatología. Complejo Asistencial Universitario de León. León. España.

^rServicio de Dermatología. Hospital Universitario Ramón y Cajal. Madrid. España.

^sServicio de Dermatología. Hospital Universitario Fundación Jiménez Díaz. Madrid. España.

^tServicio de Dermatología. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia. España.

^uServicio de Dermatología. Hospital Universitario de La Princesa. Madrid. España.

^vServicio de Dermatología. Hospital Universitario Virgen del Rocío. Sevilla. España.

^wServicio de Dermatología. Complejo Hospitalario Universitario de Toledo. Toledo. España.

^xServicio de Dermatología. Hospital Universitario Araba. Universidad del País Vasco. Vitoria. España.

^yUnidad de Investigación. Fundación Piel Sana AEDV. Madrid. España.

Autor de correspondencia: Carlos Pelayo Hernández Fernández

E-mail: cpherfer@gobiernodecanarias.org

RESUMEN

ANTECEDENTES Y OBJETIVO

El hidroxiiisohexil 3-ciclohexeno carboxaldehído (HICC), o Lyral[®], es un marcador de fragancias que forma parte de la mezcla de fragancias II (MF II) y aún se parchea como alérgeno independiente dentro de la batería estándar europea y otras baterías nacionales, pese a que la Comisión Europea prohibió su uso en cosméticos en 2021.

Nuestro objetivo es estudiar la prevalencia de sensibilización al HICC en España y la positividad simultánea con la MF II, para determinar si debería formar parte de la batería estándar española.

MATERIAL Y MÉTODO

Analizamos todos los pacientes consecutivos del Registro Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (REIDAC) parcheados simultáneamente con HICC y MF II, desde el 01 de junio de 2018 al 31 de diciembre de 2023.

RESULTADOS

De 12 029 pacientes analizados, 96 (0,8%) fueron positivos al HICC y 396 (3,3%) a la MF II, con una relevancia presente del 53% y 64%, respectivamente. 72 de los 96 (75%) pacientes sensibilizados al HICC serían detectados si solamente se parchease la MF II.

CONCLUSIONES

La prevalencia de sensibilización al HICC en España es baja y ha disminuido en los últimos años. El HICC es una fragancia prohibida en cosméticos y la MF II detecta a tres de cada cuatro pacientes sensibilizados. Nuestros resultados sugieren que el HICC debe permanecer fuera de la batería estándar española y apoyan su exclusión de la batería estándar europea.

ABSTRACT

BACKGROUND AND OBJECTIVES

Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyrall[®] is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021.

We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish standard patch test series.

MATERIAL AND METHOD

We analysed all consecutive patients simultaneously patch-tested with HICC and FM II from the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 through December 31st, 2023.

RESULTS

A total of 96 (0.8%) out of 12,029 patients analyzed tested positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II were patched.

CONCLUSIONS

Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish standard patch test series and support its exclusion from the European standard patch test series.

PALABRAS CLAVE

Dermatitis de contacto; hidroxiisohexil 3-ciclohexeno carboxaldehído; Lyrall; pruebas epicutáneas; España; batería estándar.

KEYWORDS

Contact dermatitis; hydroxyisohexyl 3-cyclohexene carboxaldehyde; Lyrall; patch tests; Spain; standard patch test series.

Introduction

Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) (CAS no. [31906-04-4]) or Lyrall[®] is a synthetic fragrance that is patch-tested independently (5% pet.) or as part of the fragrance mix II (FM II) within the European baseline series of patch tests¹, and also as part of fragrance series in patients with suspected allergic contact dermatitis (ACD). FM II (14% pet.) is composed of a total of 6 fragrances: hexyl cinnamic aldehyde (5% pet.), HICC (2.5% pet.), coumarin (2.5% pet.), farnesol (2.5% pet.), citral (1% pet.), and citronellol (0.5% pet.). Because of their importance, HICC and FM II were added as allergens to the European baseline series in 2008². In Spain, both have been included as allergens in the Spanish baseline series since 2012³, although HICC was removed from the Spanish baseline series in 2022, becoming part of the Spanish extended series⁴.

The most recent European studies indicate a decrease in the prevalence of sensitization to HICC in recent years, currently around 1%⁵⁻⁹. In most studies, the percentage of HICC-positive patients who would be missed if only FM II were patch-tested within a baseline series is approximately 15–20%. For this reason, some authors have recommended eliminating HICC from European and national baseline series⁸⁻¹³.

The primary endpoint of this study is to evaluate the frequency of sensitization to HICC in Spain during the period 2018–2023 and the simultaneous positivity to FM II to determine whether HICC should remain part of the Spanish baseline series. Secondary endpoints include assessing the clinical relevance of sensitization and the clinical-epidemiological characteristics of the sensitized population.

Materials and Methods

The Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy (REIDAC) prospectively collects clinical information from all patients studied with patch tests in participating hospitals in Spain¹⁴. We conducted an observational, cross-sectional study including unselected patients from REIDAC, consecutively and simultaneously patch-tested with HICC (5% pet.) and FM II (14% pet., of which 2.5% is HICC), as part of the Spanish baseline and the 2022 Spanish extended series, from June 1st, 2018 through December 31st, 2023.

Allergens were obtained from Chemotechnique Diagnostics[®] (Vellinge, Sweden) and allergEAZE[®] (SmartPractice, Calgary, Canada), depending on center availability. Patch tests were performed according to the clinical practice guidelines of the European Society of Contact Dermatitis (ESCD)¹⁵. Reactions scored as (+), (++) or (+++) were considered positive. Relevance (current, past, irritant, active sensitization, cross-reactivity, unknown) was determined based on clinical history. Data collected included MOAHLFA index variables (Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40 years), the patient's main occupation, and the main site of dermatitis.

Continuous variables (age) were expressed as arithmetic mean (standard deviation), and categorical variables as counts (proportions). Fisher's exact test was used as univariate analysis to study the association between MOAHLFA variables and positivity to HICC and FM II, expressed as odds ratios (OR) with 95% confidence intervals (95%CI). Results were considered significant

when $p \leq 0.05$. Statistical analyses were performed using Stata® 16 (StataCorp. 2019. Stata® Statistical Software: Release 16. College Station, TX: StataCorp LLC, RRID: SCR_012763).

Results

Sensitization and Relevance

A total of 12,029 unselected patients were studied (Table 1). The overall rate of sensitization to HICC was 0.8% (96/12,029). Of these, 53.1% (51/96) were of current relevance. The overall frequency of sensitization to FM II was 3.3% (396/12,029), of which 64.4% (255/396) were of current relevance. The proportion of weak (+), moderate (++), and strong (+++) reactions was similar in both groups.

The annual frequency of sensitization to HICC ranged between 0.56% and 1.14%, with no significant variation ($p = 0.059$) (Figure 1). Considering only cases of current relevance, the frequency ranged between 0.15% and 0.50%, with a significant decreasing trend over time ($p = 0.026$). The annual frequency of sensitization to FM II went from 2.26% to 4.02%, without significant variation ($p = 0.081$). Considering only cases of current relevance, the frequency ranged between 1.53% and 2.56%, with no significant variation ($p = 0.170$).

Simultaneous Positivity to HICC and FM II

Of HICC-positive patients, 75% (72/96) also tested positive to FM II (Table 2, Figure 2). Considering only the subgroup with current relevance, 74.5% (38/51) of HICC-positive patients also tested positive to FM II.

Of FM II-positive patients, 18.2% (72/396) also tested positive to HICC. Considering only the subgroup with current relevance, 14.9% (38/255) of FM II-positive patients also tested positive to HICC.

Factors Associated with Positivity to HICC and FM II

The MOAHLFA index of HICC-positive patients was similar to that of FM II-positive patients (Tables 3 and 4). Sensitization to HICC was not significantly associated with any MOAHLFA variable (Table 3). FM II positivity was significantly associated with higher frequency of age > 40 years ($p = 0.002$) and lower frequency of facial involvement ($p = 0.001$). Considering only the subgroup of patients with current relevance, FM II positivity was significantly associated with higher frequency of age > 40 years ($p = 0.024$) and lower frequency of facial involvement ($p = 0.028$) (Table 4).

Discussion

The prevalence of sensitization to HICC in our study was 0.8%, lower than the 1.1% observed by Silvestre et al. in 2011–2015¹⁶. In contrast, the frequency of FM II positivity remained stable at 3.3%.

In 1999, Frosch et al.¹⁷ recommended routine patch testing of HICC, and in 2005 defended the utility of FM II to detect more fragrance-sensitized patients¹⁸, which led Bruze et al. to recommend inclusion of both in the European baseline series in 2008². Since then, European studies in consecutive patients have shown a progressive decrease in HICC positivity and, to a lesser extent, FM II positivity, with current prevalences near 1% and 3%, respectively⁵⁻⁹. This decrease relates to the 2009 recommendation of the International Fragrance Association (IFRA) to reduce HICC concentration in cosmetics¹⁹ and the European Commission's definitive ban on its use in cosmetics in 2017, effective August 23rd, 2021²⁰.

Significant variability exists in the prevalence of allergy to fragrance markers across European centers²¹. Within the Information Network of Departments of Dermatology (IVDK), Geier et al.^{6,22}, Uter et al.²³, Krautheim et al.²⁴, and Schnuch et al.^{25,26} demonstrated a decline in HICC and FM II positivity from 2.6% and 5% in 1995 down to 1.1% and 3% in 2021, respectively. Similarly, though less markedly, HICC sensitization decreased significantly in the European Surveillance System on Contact Allergies (ESSCA), as shown by Uter et al.^{7,27,28}, Ahlström et al.⁸, and Frosch et al.²⁹, from 1.7% in 2009 down to 1.3% in 2020, with FM II remaining stable at 3.8%. In an International Contact Dermatitis Research Group (ICDRG) study from 2012–2016, Bruze et al.⁹ found HICC and FM II positivity frequencies of 1.6% and 3.9%, respectively. In another multicenter European cohort (2008–2011), Diepgen et al.³⁰ observed respective frequencies of 1.5% and 1.9%.

In Sweden, HICC and FM II allergy prevalence was studied by Andernord et al.³¹, Engfeldt et al.¹², and Isaksson et al.¹⁰ within the Swedish Contact Dermatitis Research Group (SCDRG), and by Sukakul et al.¹³ and Mowitz et al.³² in Malmö Hospital, decreasing from peaks of 1.7% and 3.4% in 2006 down to lows of 1% and 2.3% in 2020, respectively. Within SIDAPA (Società Italiana Dermatologia Allergologica Professionale Ambientale) during 2016–2021, Stingeni et al.⁵ reported respective prevalences of 1% and 2.1%. At Gentofte Hospital (Copenhagen, Denmark), Ahlström et al.⁸ observed a decrease in HICC sensitization from > 2% in 2009 down to 1% in 2019. At St. John's Hospital (London, UK), Mann et al.³³ and Ung et al.³⁴ found HICC and FM II prevalences stable at 1.4% and 2.9%, respectively. At Leuven Hospital (Belgium), Nardelli et al.³⁵ observed decreasing HICC sensitization from 2007 to 2011 (mean 2.1%), while FM II remained stable (mean 6%).

In our study, allergy to HICC and FM II was clinically relevant in over half of patients, which is consistent with prior reports^{5,8,21,30}. The proportion of moderate/strong (++) reactions was 58% and 56% for HICC and FM II, respectively, with low rates of irritant/doubtful reactions.

Of all HICC positives, 75% were detected by FM II, a percentage similar to that observed in cases with clinically relevant allergy to both allergens. In the literature, the proportion of FM II-positive, HICC-negative patients ranges from 10%^{34,35} to 24%^{5,8,29}, averaging 15–20% in most studies^{9,10,12,22,24}. Given these findings and the decline in HICC sensitization, several authors have advocated removal of HICC from national and European baseline series (except Stingeni et al.⁵). Indeed, the SCDRG eliminated HICC from the Swedish baseline series in 2014¹⁰, and the ICDRG adopted the same decision for the international baseline series in 2020¹¹. This ultimately led to exclusion of HICC from the new 2022 Spanish baseline series⁴, moving it to the Spanish extended series—a decision supported by our findings. Considering the European Commission's ban on HICC in cosmetics³⁶, sensitization is expected to continue declining. Nonetheless, to

continue documenting this trend and given the lack of regulation of HICC use in cosmetics in non-European markets, we recommend continuing HICC patch testing within the Spanish and European extended series.

In our study, no MOAHLFA variables were associated with HICC positivity, while FM II positivity was significantly associated with age > 40 years and inversely with facial dermatitis. In the literature, female sex and age > 40 years are often associated with positivity to HICC^{5, 8, 10, 25, 29, 30, 37} and FM II^{5, 10, 24, 38}. Occupational dermatitis, atopic dermatitis, and facial dermatitis have been occasionally associated with HICC^{8, 37} and FM II^{6, 24, 38}. In our patients, the most frequent sites were hands, trunk, and face for both HICC (Table 3) and FM II (Table 4), consistent with fragrance ACD typically affecting hands, face, neck, and axillae^{21, 38, 39}. Interestingly, in our cohort facial dermatitis was negatively associated with FM II positivity, possibly because we only analyzed the main site without considering multiple locations. Additionally, several studies link hand involvement with FM II positivity^{6, 16, 24, 38}, while leg involvement has been negatively associated with HICC sensitization^{8, 16, 25, 37, 40}.

In our population, occupational ACD cases were rare, at 3% for HICC and 10% for FM II. The most frequent occupations were administrative staff, service sector employees, homemakers, and healthcare workers, with no major differences by relevance (Tables 3 and 4). In general, occupational ACD due to fragrances is uncommon, mainly involving the perfume/cosmetics, domestic cleaning, aesthetics/hairdressing, health care, food, metalworking, and aromatherapy industries^{21, 39}. However, Montgomery et al.⁴¹ observed a gradual increase in occupational fragrance ACD cases reported in the UK during 1996–2015.

Conclusions

The prevalence of sensitization to HICC in Spain has decreased in recent years, currently standing at 0.8%. Half of the cases are clinically relevant. FM II detects 3 of every 4 patients sensitized to HICC. Our results support keeping HICC outside the Spanish baseline series and within the Spanish extended series and highlight the need to consider its transfer from the European baseline series to the European extended series.

Funding

REIDAC is promoted by the Spanish Academy of Dermatology and Venereology (AEDV, Fundación Piel Sana), which has received funding from the Spanish Agency of Medicines and Medical Devices (AEMPS) (BOE reference) and Sanofi®. The funding sources had no role in study conception, design, data collection, analysis, interpretation, manuscript preparation, review, approval, or logistical support.

Conflicts of interest

None declared.

Acknowledgments

The authors thank Dr. Francisco Javier Ortiz de Frutos (*Hospital Universitario 12 de Octubre*, Madrid, Spain) for providing data from his center, and Ms. Marina de Vega (AEDV Research Unit) for her support in maintaining the registry. This work is part of the doctoral thesis of Carlos Pelayo Hernández Fernández at *Universidad de Las Palmas de Gran Canaria* (ULPGC) (Canary Islands, Spain).

References

1. Wilkinson SM, Gonçalo M, Aerts O, et al. The European baseline series and recommended additions: 2023. *Contact Dermatitis*. Feb 2023;88(2):87-92. doi:10.1111/cod.14255
2. Bruze M, Andersen KE, Goossens A. Recommendation to include fragrance mix 2 and hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyal) in the European baseline patch test series. *Contact Dermatitis*. Mar 2008;58(3):129-33. doi:10.1111/j.1600-0536.2007.01292.x
3. Arribas MP, Soro P, Silvestre JF. Dermatitis de contacto alérgica por fragancias. Parte II. 10.1016/j.ad.2012.03.005. *Actas Dermo-Sifiliográficas*. 2013;104(1):29-37. doi:10.1016/j.ad.2012.03.005
4. Navarro-Triviño FJ, Borrego L, Silvestre-Salvador JF, et al. Actualización de la batería estándar y batería ampliada de pruebas alérgicas de contacto por el Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC). *Actas Dermo-Sifiliográficas*. 2024/03/29/ 2024;doi:https://doi.org/10.1016/j.ad.2024.03.024
5. Stingeni L, Hansel K, Corazza M, et al. Contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Italy: Prevalence, trend, and concordance with fragrance mix II. *Contact Dermatitis*. Feb 2023;88(2):129-133. doi:10.1111/cod.14240
6. Geier J, Schubert S, Rieker-Schwiebacher J, et al. Declining frequency of sensitization to fragrance mixes I and II: IVDK-data of the years 2012-2021. *Contact Dermatitis*. Dec 25 2023;doi:10.1111/cod.14493
7. Uter W, Wilkinson SM, Aerts O, et al. Patch test results with the European baseline series, 2019/20-Joint European results of the ESSCA and the EBS working groups of the ESCD, and the GEIDAC. *Contact Dermatitis*. Oct 2022;87(4):343-355. doi:10.1111/cod.14170
8. Ahlström MG, Uter W, Johansen JD. Decrease of contact allergy to hydroxyisohexyl 3-cyclohexene carboxaldehyde in Europe prior to its ban and diagnostic value. *Contact Dermatitis*. Jun 2021;84(6):419-422. doi:10.1111/cod.13786
9. Bruze M, Ale I, Andersen KE, et al. Contact Allergy to Fragrance Mix II and Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde: A Retrospective Study by International Contact Dermatitis Research Group. *Dermatitis*. Jul/Aug 2020;31(4):268-271. doi:10.1097/der.0000000000000545
10. Isaksson M, Inerot A, Lidén C, et al. Multicentre patch testing with fragrance mix II and hydroxyisohexyl 3-cyclohexene carboxaldehyde by the Swedish Contact Dermatitis Research Group. *Contact Dermatitis*. Mar 2014;70(3):187-9. doi:10.1111/cod.12156
11. Isaksson M, Ale I, Andersen KE, et al. Revised Baseline Series of the International Contact Research Group. *Dermatitis*. Jan/Feb 2020;31(1):e5-e7. doi:10.1097/der.0000000000000532

12. Engfeldt M, Hagvall L, Isaksson M, et al. Patch testing with hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) - a multicentre study of the Swedish Contact Dermatitis Research Group. *Contact Dermatitis*. Jan 2017;76(1):34-39. doi:10.1111/cod.12699
13. Sukakul T, Bruze M, Mowitz M, et al. Simultaneous patch testing with fragrance markers in the baseline series and the ingredients of fragrance mixes: An update from southern Sweden. *Contact Dermatitis*. Jun 2022;86(6):514-523. doi:10.1111/cod.14072
14. Hernández-Fernández CP, Mercader-García P, Silvestre Salvador JF, et al. Candidate Allergens for Inclusion in the Spanish Standard Series Based on Data from the Spanish Contact Dermatitis Registry. *Actas Dermosifiliogr*. 2021;112(9):798-805. Alérgenos candidatos para ser incluidos en la serie estándar española a partir de los datos del Registro Español de Dermatitis de Contacto. doi:10.1016/j.adengl.2021.07.013
15. Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. *Contact Dermatitis*. Oct 2015;73(4):195-221. doi:10.1111/cod.12432
16. Silvestre JF, Mercader P, González-Pérez R, et al. Sensitization to fragrances in Spain: A 5-year multicentre study (2011-2015). *Contact Dermatitis*. Feb 2019;80(2):94-100. doi:10.1111/cod.13152
17. Frosch PJ, Johansen JD, Menné T, et al. Lyril is an important sensitizer in patients sensitive to fragrances. *Br J Dermatol*. Dec 1999;141(6):1076-83. doi:10.1046/j.1365-2133.1999.03208.x
18. Frosch PJ, Pirker C, Rastogi SC, et al. Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix. *Contact Dermatitis*. Apr 2005;52(4):207-15. doi:10.1111/j.0105-1873.2005.00565.x
19. Api A M, Vey M. A new IFRA standard on the fragrance ingredient, hydroxyisohexyl 3-cyclohexene carboxaldehyde. *Contact Dermatitis* 2010; 62: 254–255.
20. Commission Regulation (EU) 2017/1410 of 2 August 2017 amending Annexes II and III to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products. *Off. J. Eur. Union* 2017;L202:1. Available at: <https://eur-lex.europa.eu/eli/reg/2017/1410/oj> (last accessed 05 May 2024).
21. de Groot AC. Fragrances: Contact Allergy and Other Adverse Effects. *Dermatitis*. Jan/Feb 2020;31(1):13-35. doi:10.1097/der.0000000000000463
22. Geier J, Uter W, Lessmann H, Schnuch A. Fragrance Mix I and II - results of breakdown tests. *Flavour and Fragrance Journal*. 03/01 2015;30doi:10.1002/ffj.3247
23. Uter W, Gefeller O, Mahler V, Geier J. Trends and current spectrum of contact allergy in Central Europe: results of the Information Network of Departments of Dermatology (IVDK) 2007-2018. *Br J Dermatol*. Nov 2020;183(5):857-865. doi:10.1111/bjd.18946
24. Krautheim A, Uter W, Frosch P, Schnuch A, Geier J. Patch testing with fragrance mix II: results of the IVDK 2005-2008. *Contact Dermatitis*. Nov 2010;63(5):262-9. doi:10.1111/j.1600-0536.2010.01753.x
25. Schnuch A, Uter W, Geier J, Lessmann H, Frosch PJ. Sensitization to 26 fragrances to be labelled according to current European regulation. Results of the IVDK and review of the literature. *Contact Dermatitis*. Jul 2007;57(1):1-10. doi:10.1111/j.1600-0536.2007.01088.x
26. Schnuch A, Geier J, Uter W. Is hydroxyisohexyl 3-cyclohexene carboxaldehyde sensitization declining in central Europe? *Contact Dermatitis*. Jul 2012;67(1):47-9. doi:10.1111/j.1600-0536.2012.02126.x

27. Uter W, Bauer A, Belloni Fortina A, et al. Patch test results with the European baseline series and additions thereof in the ESSCA network, 2015-2018. *Contact Dermatitis*. Feb 2021;84(2):109-120. doi:10.1111/cod.13704
28. Uter W, Amario-Hita JC, Balato A, et al. European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14. *J Eur Acad Dermatol Venereol*. Sep 2017;31(9):1516-1525. doi:10.1111/jdv.14423
29. Frosch PJ, Duus Johansen J, Schuttelaar ML, et al. Patch test results with fragrance markers of the baseline series - analysis of the European Surveillance System on Contact Allergies (ESSCA) network 2009-2012. *Contact Dermatitis*. Sep 2015;73(3):163-71. doi:10.1111/cod.12420
30. Diepgen TL, Ofenloch R, Bruze M, et al. Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. *Br J Dermatol*. Dec 2015;173(6):1411-9. doi:10.1111/bjd.14151
31. Andernord D, Bruze M, Bryngelsson IL, et al. Contact allergy to haptens in the Swedish baseline series: Results from the Swedish Patch Test Register (2010 to 2017). *Contact Dermatitis*. Mar 2022;86(3):175-188. doi:10.1111/cod.13996
32. Mowitz M, Svedman C, Zimerson E, Isaksson M, Pontén A, Bruze M. Simultaneous patch testing with fragrance mix I, fragrance mix II and their ingredients in southern Sweden between 2009 and 2015. *Contact Dermatitis*. Nov 2017;77(5):280-287. doi:10.1111/cod.12834
33. Mann J, McFadden JP, White JM, White IR, Banerjee P. Baseline series fragrance markers fail to predict contact allergy. *Contact Dermatitis*. May 2014;70(5):276-81. doi:10.1111/cod.12171
34. Ung CY, White JML, White IR, Banerjee P, McFadden JP. Patch testing with the European baseline series fragrance markers: a 2016 update. *Br J Dermatol*. Mar 2018;178(3):776-780. doi:10.1111/bjd.15949
35. Nardelli A, Carbonez A, Drieghe J, Goossens A. Results of patch testing with fragrance mix 1, fragrance mix 2, and their ingredients, and Myroxylon pereirae and colophonium, over a 21-year period. *Contact Dermatitis*. May 2013;68(5):307-13. doi:10.1111/cod.12056
36. Commission Regulation (EU) 2017/1410 of 2 August 2017 amending Annexes II and III to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products. *Off. J. Eur. Union* 2017;L202:1. Available at: <https://eur-lex.europa.eu/eli/reg/2017/1410/oj> (last accessed 22 October 2023).
37. Uter W, Geier J, Schnuch A, Gefeller O. Risk factors associated with sensitization to hydroxyisohexyl 3-cyclohexene carboxaldehyde. *Contact Dermatitis*. Aug 2013;69(2):72-7. doi:10.1111/cod.12069
38. Uter W, Fießler C, Gefeller O, Geier J, Schnuch A. Contact sensitization to fragrance mix I and II, to Myroxylon pereirae resin and oil of turpentine: Multifactorial analysis of risk factors based on data of the IVDK network. *Flavour and Fragrance Journal*. 04/01 2015;30doi:10.1002/ffj.3242
39. Arribas MP, Soro P, Silvestre JF. Dermatitis de contacto alérgica por fragancias. Parte I. 10.1016/j.ad.2012.01.015. *Actas Dermo-Sifiliográficas*. 2012;103(10):874-879. doi:10.1016/j.ad.2012.01.015
40. Sánchez-Pujol MJ, Docampo-Simón A, Mercader P, et al. Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index. *Contact Dermatitis*. Jun 2021;84(6):395-406. doi:10.1111/cod.13801

41. Montgomery RL, Agius R, Wilkinson SM, Carder M. UK trends of allergic occupational skin disease attributed to fragrances 1996-2015. *Contact Dermatitis*. Jan 2018;78(1):33-40. doi:10.1111/cod.12902

Journal Pre-proof

Figure 1. Annual variation in positivity frequency to hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrál) and fragrance mix II (FM II). Solid lines illustrate annual variation for all positives (Lyrál: blue line; FM II: brown line) and positives with current relevance (Lyrál: green line; FM II: orange line). Dashed lines illustrate trend variation for all positives (Lyrál: green line; FM II: red line) and positives with current relevance (Lyrál: blue line; FM II: yellow line).




Figure 2. Simultaneous positivity between hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyrál) and Fragrance Mix II (FM II). A) Simultaneous positivity between Lyrál and FM II among all positives. B) Simultaneous positivity between Lyrál and FM II among positives with current relevance.




Table 1. Frequency of positives and relevance to hydroxyisohexyl 3-cyclohexene carboxaldehyde and Fragrance Mix II

	Reactions						Relevance					
	Positive											
	All (% ^a)	+ (% ^b)	++ (% ^b)	+++ (% ^b)	Irritant (% ^a)	Doubtful ?+ (% ^a)	Current (%)	Past (%)	Irritant (%)	Active sensitization (%)	Cross- reactivity (%)	Unknown (%)
HICC	96 (0.8)	40 (41)	43 (45)	13 (14)	1 (0.01)	14 (0.1)	51 (53.1)	13 (13.5)	1 (1.0)	0 (0)	0 (0)	31 (32,3)
FM II	396 (3.3)	176 (44)	172 (43)	48 (12)	1 (0.01)	52 (0.4)	255 (64.4)	27 (6.8)	11 (2.8)	2 (0.5)	1 (0.3)	100 (25,3)

HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; FM II: Fragrance Mix II.

^a Percentage over the total patch-tested (n = 12,029).

^b Percentage over the total positives.

Table 2. Frequency of negatives and simultaneous positives to hydroxyisohexyl 3-cyclohexene carboxaldehyde and Fragrance Mix II

	FM II		Total
	Negatives	Positives	
<i>HICC</i>			
Negatives (% ^a)	11,609 (97.3)	324 (2.7)	11,933
Positives (% ^b)	24 (25)	72 (75)	96
<i>Total</i>	11,633	396	12,029

HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; FM II: Fragrance Mix II.

^a Percentage over the total HICC-negative (n = 11,933).

^b Percentage over the total HICC-positive (n = 96).

Journal Pre-proof

Table 3. Population characteristics and odds ratios for positivity to hydroxyisohexyl 3-cyclohexene carboxaldehyde

	HICC, all patch-tested (%)	HICC, negatives (%)	HICC, positives (%)	OR (95%CI)	HICC, positives with current relevance (%)	OR (95%CI)
Total	12,029 (100)	11,933 (99.2 ^a)	96 (0.8 ^a)		51 (0.4 ^a)	
<i>MOAHLFA</i>						
▫ Sex (M)	3,635 (30)	3,610 (30)	25 (26)	0.8 (0.5–1.3)	15 (29)	1.0 (0.5–1.8)
▫ Occupational (O)	1,069 (9)	1,066 (9)	3 (3)	0.3 (0.1–1.1)	1 (2)	0.2 (0.03–1.5)
▫ Atopic dermatitis (A)	2,228 (19)	2,207 (19)	21 (22)	1.2 (0.75–2)	12 (24)	1.3 (0.7–2.6)
▫ Hand location (H)	3,721 (31)	3,698 (31)	23 (24)	0.7 (0.4–1.1)	11 (22)	0.6 (0.3–1.2)
▫ Leg location (L)	609 (5)	607 (5)	2 (2)	0.4 (0.1–1.6)	2 (4)	0.8 (0.2–3.1)
▫ Face location (F)	2,869 (24)	2,849 (24)	20 (21)	0.8 (0.5–1.4)	11 (22)	0.9 (0.45–1.7)
▫ Age > 40 years (A)	8,124 (68)	8,057 (68)	67 (70)	1.1 (0.7–1.7)	30 (59)	0.7 (0.4–1.2)
▫ Mean age (SD)	48.4 (18.3)	48.4 (18.0)	48.4 (18.6)	1.0 (0.99–1.01)	47.2 (15.4)	1.0 (0.98–1.01)
<i>Main occupation</i>						
▫ Administrative	1,341 (11)	1,314 (11)	27 (28)		14 (27)	
▫ Service sector	607 (5)	595 (5)	12 (13)		6 (12)	
▫ Retired	2,091 (17)	2,079 (17)	12 (13)		5 (10)	
▫ Homemaker	1,151 (10)	1,145 (10)	6 (6)		4 (8)	
▫ Health care	897 (7)	892 (7)	5 (5)		4 (8)	
▫ Other/unknown	5,942 (49)	5,908 (50)	34 (35)		18 (35)	
<i>Main site of dermatitis</i>						
▫ Hands	3,721 (31)	3,698 (31)	23 (24)		11 (22)	
▫ Legs	609 (5)	607 (5)	2 (2)		2 (4)	
▫ Face	2,869 (24)	2,849 (24)	20 (21)		11 (22)	
▫ Trunk	1,868 (16)	1,847 (16)	21 (22)		14 (27)	
▫ Neck	350 (3)	343 (3)	7 (7)		5 (10)	
▫ Other/unknown	2,612 (22)	2,589 (22)	23 (24)		8 (16)	

SD: standard deviation; HICC: hydroxyisohexyl 3-cyclohexene carboxaldehyde; 95%CI: 95% confidence interval; MOAHLFA: Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40; OR: odds ratio.

^a Percentage over all patch-tested (n = 12,029).

Table 4. Population characteristics and odds ratios for positivity to Fragrance Mix II

	FM II, all patch- tested (%)	FM II, negatives (%)	FM II, positives (%)	OR (95%CI)	FM II, positives with current relevance (%)	OR (95%CI)
Total	12,029 (100)	11,633 (96.7 ^a)	396 (3.3 ^a)		255 (2.1 ^a)	
<i>MOAHLFA</i>						
▫ Sex (M)	3,635 (30)	3,506 (30)	129 (33)	1.1 (0.9– 1.4)	87 (34)	1.2 (0.9– 1.6)
▫ Occupational (O)	1,069 (9)	1,032 (9)	37 (10)	1.1 (0.75– 1.5)	22 (9)	1.0 (0.6– 1.5)
▫ Atopic dermatitis (A)	2,228 (19)	2,160 (19)	68 (17)	0.9 (0.7– 1.2)	42 (17)	0.9 (0.6– 1.2)
▫ Hand location (H)	3,721 (31)	3,597 (31)	124 (31)	1.0 (0.8– 1.3)	68 (27)	0.8 (0.6– 1.1)
▫ Leg location (L)	609 (5)	585 (5)	24 (6)	1.2 (0.8– 1.85)	18 (7)	1.4 (0.9– 2.3)
▫ Face location (F)	2,869 (24)	2,804 (24)	65 (16)	0.6 (0.5– 0.8)	46 (18)	0.7 (0.5– 0.96)
▫ Age > 40 years (A)	8,124 (68)	7,829 (68)	295 (75)	1.4 (1.1– 1.8)	189 (74)	1.4 (1.04– 1.85)
▫ Mean age (SD)	48.4 (18.3)	48.3 (18.0)	51.1 (17.7)	1.0 (1.00– 1.01)	50.9 (18.8)	1.0 (1.00– 1.01)
<i>Main occupation</i>						
▫ Administrative	1,341 (11)	1,283 (11)	58 (15)		39 (15)	
▫ Service sector	607 (5)	586 (5)	21 (5)		12 (5)	
▫ Retired	2,091 (17)	2,005 (17)	86 (22)		52 (20)	
▫ Homemaker	1,151 (10)	1,128 (10)	23 (6)		17 (7)	
▫ Health care	897 (7)	865 (7)	32 (8)		17 (7)	
▫ Other/unknown	5,906 (49)	5,766 (50)	140 (35)		137 (54)	
<i>Main site of dermatitis</i>						
▫ Hands	3,721 (31)	3,597 (31)	124 (31)		68 (27)	
▫ Legs	609 (5)	585 (5)	24 (6)		18 (7)	
▫ Face	2,869 (24)	2,804 (24)	65 (16)		46 (18)	
▫ Trunk	1,868 (16)	1,785 (15)	83 (21)		61 (24)	
▫ Neck	350 (3)	334 (3)	16 (4)		11 (4)	
▫ Other/unknown	2,612 (22)	2,528 (22)	84 (21)		51 (20)	

Statistically significant variables ($p \leq 0.05$) are italicized.

SD: standard deviation; 95%CI: 95% confidence interval; MOAHLFA: Male, Occupational dermatitis, Atopic dermatitis, Hand dermatitis, Leg dermatitis, Face dermatitis, Age > 40; OR: odds ratio.

^a Percentage over all patch-tested (n = 12,029).

Journal Pre-proof

TRADUCCIÓN DE FIGURAS
(COLOR NEGRO: ESPAÑOL · AZUL: INGLÉS)

Figura 1

Año

Lyrál

Lyrál (relevante)

Tend. Lyrál

Tend. Lyrál (rel)

Mez. Frag. II

Mez. Frag. II (relevante)

Tend. Frag.

Tend. Frag. (rel)

Year

Lyrál

Lyrál (current relevance)

Lyrál trend

Lyrál trend (current relevance)

Fragrance Mix II

Fragrance Mix II (current relevance)

Fragrance Mix II trend

Fragrance Mix II trend (current relevance)

Figura 2

Mez. Frag. II

Lyrál

Fragrance Mix II

Lyrál



ELSEVIER

Advancing human progress *together*

Journal Pre-proof